By Willem Kanyondi
What the New State-Hospital Tariff Costs the Private Funding Pool
MHSS has tripled the cost of admitting a private patient to a state facility. The funders who were not named in the announcement are now carrying the risk — and the questions worth asking next are about design, not blame.
For most of the past two decades, the conversation about cross-subsidisation in Namibian healthcare ran in one direction.
The private sector argued — with reasonable evidence — that medical aid funds were carrying part of the cost of the state system, because public facilities under-billed private patients and the gap was made up by general taxation.
The State’s reply was that public tariffs sat below cost by design, and that this was the social contract.
On 3 June 2026, the Ministry of Health and Social Services moved the cost recovery for a private patient admitted to a state facility from approximately N$600 per night to N$2,030 per night.
The Ministry’s media release framed this as a “long-overdue tariff realignment.” It is overdue — the previous tariffs had not been comprehensively reviewed for eleven years. It is also a 238% increase — a 3.4x multiplier — and the release did not quantify what that multiplier costs the funders who pay it.
That is the question worth working through, because the answer determines whether this is a routine tariff adjustment or a structural shift in the financing of Namibian healthcare.
Who actually pays
The Ministry’s release was carefully scoped. It reassured PSEMAS members that their tariffs remain within scheme funding levels and that they will not face out-of-pocket costs.
This is true for PSEMAS principal members and their dependants — they sit inside a fund whose tariffs are set by Treasury and whose budget can absorb the increase as a matter of intergovernmental accounting.
The release was silent on every other funder. NMC, NHP, Renaissance, Prosperity Health, the MVA Fund and the rest of the private medical aid landscape are not mentioned. Their members are also admitted to state facilities — particularly in regions where state hospitals are the closest, the only, or the most appropriate provider for a particular service.
Those funds have just absorbed a 3.4x cost increase per admission day, with no consultation visible in the document, no transition period, and no negotiated framework.
That cost does not vanish into a Treasury budget. It surfaces in three places: higher contribution rates at the next benefit-review cycle, tighter benefit caps, or claims scrutiny pushed downstream onto providers — and in practice, in some combination of all three.
The risk has been transferred from the State’s balance sheet to the private medical aid pool. That is the structural shift the release did not quantify.
The competitive geometry
The second consequence is one of pricing relative to private hospitals. Per the Ministry’s own illustration, a private hospital admission reimburses at approximately N$2,900 per night versus a public-facility admission now at N$2,030.
The premium that a private medical aid pays to send a member private has dropped from nearly 5x to roughly 1.4x in a single announcement.
Private hospitals remain the higher-quality option for many procedures, and that is the defensible margin. But the pricing argument — the one funders have used for years to justify routing patients toward private facilities — has weakened materially.
Expect funder-level utilisation reviews to begin asking, procedure by procedure, whether the clinical case for a private admission justifies a 40% cost premium where the clinical answer is “yes for some, no for others.”
Toward a design conversation
None of this is an argument against tariff reform. The previous tariff structure was unsustainable, and a state system that cannot recover the cost of treating private patients is one that defers infrastructure investment indefinitely.
The question is not whether to adjust, but how to land the adjustment without creating systemic risk in the financing pool the country still relies on. A few design moves are worth considering.
A phased transition for non-PSEMAS funders. The PSEMAS tariff was adjusted inside a budget framework that the Ministry of Finance had already approved. Non-PSEMAS funds did not have that lead time.
A 24-to-36 month phased introduction — stepped, for example, at 50%, 75% and 100% of the new tariff — would allow these funds to adjust contribution structures and benefit designs without the shock landing in a single benefit-review cycle.
A phased introduction would allow non-PSEMAS funds the same adjustment runway that PSEMAS effectively received through the Cabinet budget framework
A negotiated framework agreement. Treasury or Ministry of Finance negotiates the PSEMAS tariff with MHSS as a matter of internal government coordination. Nothing prevents an equivalent framework between MHSS and the wider funder community, mediated by NAMFISA in its new role as the FIMA regulator of medical aid funds. A standing tariff negotiation forum would replace ad-hoc adjustments with predictable, multi-year cycles which is what every mature health-financing system eventually builds.
A joint cost-data working group. The tariff debate is currently conducted with one party — the Ministry — holding the cost data, and another party — the funds — holding the claims data. Neither side has the full picture. A NAMFISA-convened working group with audited cost inputs from state facilities and audited utilisation inputs from funds would put the next tariff conversation on an evidence base rather than a press-release base.
Reinvestment accountability. The release stated that the increased revenue will enable “reinvestment into infrastructure, equipment, and service quality.” This is the right intent, and it is also the easiest claim to make and the hardest to verify.
Publishing an annual reinvestment report — showing, per facility, what the additional revenue funded — would convert a promise into a measurable commitment. It would also strengthen the Ministry’s position when the next tariff cycle arrives.
Modernised utilisation management. The cost pressure on funds will eventually force changes in pre-authorisation and admission-review processes. Done badly, this means more rejections and more friction for patients and providers.
Done well, it means clearer clinical criteria, faster decisions, and lower administrative burden. The funder community would benefit from a shared utilisation-criteria framework — currently each fund builds its own —to reduce documentation overhead on providers.
The bottom line
The Cabinet tariff decision is being reported as a price increase. It is more accurately a transfer— of cost, and therefore of risk, from the State to the private funding pool. That transfer is defensible. The system needs the cost recovery, and a state hospital cannot remain in service without it. But the design of the transfer matters as much as the principle, and the design is, at the moment, incomplete.
The question for the rest of 2026 is whether the Ministry, NAMFISA and the funder community will build the negotiation, transparency and transition mechanisms that turn this tariff correction into a sustainable financing architecture — or whether the next cycle will arrive as another single-document announcement.
The first path leads toward Universal Health Coverage. The second leads toward contribution shocks, benefit erosion, and the slow unravelling of the funding pool the country needs to keep intact.
The arithmetic is on the table. The design conversation is the one still to be had.
*Willem Kanyondi is a nurse practitioner turned clinical auditor and CIMA candidate, specialising in healthcare revenue integrity and risk. He writes on the intersection of clinical operations, financial management and healthcare financing. He writes here in his personal capacity.
